The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
#IACH2024
CONGRESS | @TheIACH #IACH2024 | POSTER
— Multiple Myeloma Hub (@MM_Hub) September 20, 2024
Zaineb Hasnaoui presents results from a retrospective analysis of patients with NDMM who underwent auto-HSCT.
The presentation characteristics and long-term outcomes were similar between patients aged ≤45 years and >45 years.
Follow our… pic.twitter.com/95RV7wBf9Z
CONGRESS | @TheIACH #IACH2024 | POSTER
— Multiple Myeloma Hub (@MM_Hub) September 20, 2024
Esther Ortega Vida, University Hospital of Jerez de la Frontera, shares findings from a real-world, single-center, retrospective study of the impact of novel therapies on survival in patients with MM.
Findings suggest that incorporating… pic.twitter.com/fSZpr7n4Ki
CONGRESS | @TheIACH #IACH2024 | POSTER
— Multiple Myeloma Hub (@MM_Hub) September 21, 2024
Zaineb Hasnaoui reports results from a retrospective analysis of the outcomes of patients with multiple myeloma and renal impairment who were treated with VTD triplet therapy and underwent auto-HSCT.
Survival outcomes in patients receiving… pic.twitter.com/avFcJTGZyz
CONGRESS | @TheIACH #IACH2024 | PRESENTATION
— Multiple Myeloma Hub (@MM_Hub) September 21, 2024
Thierry Facon @univ_lille provides an update on treatment for elderly patients with NDMM.
They highlight results from IMROZ and BENEFIT trials, and discuss clinical considerations and potential future directions for the treatment of… pic.twitter.com/24i8LIl47T
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content